Evidence map›Paper›PMID 30458879›Full record

ArticleBreast cancer research : BCR2018

Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer.

Marcus Vetter, Julia Landin, Barbara Maria Szczerba, Francesc Castro-Giner, Sofia Gkountela, Cinzia Donato, Ilona Krol, Ramona Scherrer, Catharina Balmelli, Alexandra Malinovska and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Concomitant medications and circulating tumor cells: friends or foes?Cancer drug resistance (Alhambra, Calif.) · 2023
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Marcus VetterGynecologic Cancer Center, University Hospital Basel, 4056, Basel, Switzerland.
Julia LandinDepartment of Medical Oncology, University Hospital Basel, 4056, Basel, Switzerland.
Barbara Maria SzczerbaDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.
Francesc Castro-GinerDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.
Sofia GkountelaDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.
Cinzia DonatoDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.
Ilona KrolDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.
Ramona ScherrerDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland.
Catharina BalmelliDepartment of Medical Oncology, University Hospital Basel, 4056, Basel, Switzerland.
Alexandra MalinovskaDepartment of Medical Oncology, University Hospital Basel, 4056, Basel, Switzerland.
Alfred ZippeliusDepartment of Medical Oncology, University Hospital Basel, 4056, Basel, Switzerland.
Christian KurzederGynecologic Cancer Center, University Hospital Basel, 4056, Basel, Switzerland.
Viola Heinzelmann-SchwarzGynecologic Cancer Center, University Hospital Basel, 4056, Basel, Switzerland.
Walter Paul WeberBreast Center, University Hospital Basel, 4056, Basel, Switzerland.
Christoph RochlitzDepartment of Medical Oncology, University Hospital Basel, 4056, Basel, Switzerland.
Nicola AcetoDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Mattenstrasse 28, CH-4058, Basel, Switzerland. nicola.aceto@unibas.ch.ORCID 0000-0001-9579-6918
University Hospital of Basel · CHUniversity of Basel · CHSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe presence of circulating tumor cells (CTCs) in patients with breast cancer correlates to a bad prognosis. Yet, CTCs are detectable in only a minority of patients with progressive breast cancer, and factors that influence the abundance of CTCs remain elusive.

methodsWe conducted CTC isolation and enumeration in a selected group of 73 consecutive patients characterized by progressive invasive breast cancer, high tumor load and treatment discontinuation at the time of CTC isolation. CTCs were quantified with the Parsortix microfluidic device. Clinicopathological variables, blood counts at the time of CTC isolation and detailed treatment history prior to blood sampling were evaluated for each patient.

resultsAmong 73 patients, we detected at least one CTC per 7.5 ml of blood in 34 (46%). Of these, 22 (65%) had single CTCs only, whereas 12 (35%) featured both single CTCs and CTC clusters. Treatment with the monoclonal antibody denosumab correlated with the absence of CTCs, both when considering all patients and when considering only those with bone metastasis. We also found that low red blood cell count was associated with the presence of CTCs, whereas high CA 15-3 tumor marker, high mean corpuscular volume, high white blood cell count and high mean platelet volume associated specifically with CTC clusters.

conclusionsIn addition to blood count correlatives to single and clustered CTCs, we found that denosumab treatment associates with most patients lacking CTCs from their peripheral circulation. Prospective studies will be needed to validate the involvement of denosumab in the prevention of CTC generation.

Indexed as

ErythrocytesAgedAntineoplastic AgentsBreastBreast NeoplasmsCell CountDenosumabDisease ProgressionFemaleHumansMicrofluidic Analytical TechniquesMiddle AgedNeoplasm InvasivenessNeoplastic Cells, CirculatingPrognosisRetrospective StudiesAntineoplastic AgentsDenosumabBreast cancerCirculating tumor cell clustersCirculating tumor cellsDenosumabMetastasis

Identifiers

PMID30458879
PMCPMC6247738
OpenAlexW2901533874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.